Sanofi Pasteur, the vaccine arm for the drugmaker, named David Loew as its new SVP of global commercial operations. Damian Braga, who held the role previously, retired after 27 years with the drugmaker.
Loew will now lead “the development and implementation of Sanofi Pasteur’s commercial strategy,” across business units, countries and support functions, according to an email from a company spokesperson. He will be based at the company’s headquarters in Lyon, France.
The company said the appointment will not affect relationships with any of its marketing agencies nor will it affect its commercial strategy or the execution of that strategy.
Loew joined Sanofi from Roche in May 2013. At Roche, he served as regional head for Eastern Europe, Middle East and Africa at the time. Loew spent 21 years at Roche, first joining the drugmaker as a sales rep in 1992.
Sanofi Pasteur’s vaccines business brought in over $645 million in revenue for the first nine months of 2015. Its portfolio includes influenza vaccine Fluzone.
The company in December received approval for its dengue fever vaccine, Dengvaxia, in Brazil and Mexico. Dengvaxia is the first vaccine approved for the prevention of dengue fever. The French drugmaker has said it expects the vaccine to be licensed in 20 countries.
